Price$5.39-3.11 (-36.59%)
2026-03-042026-06-05
News · 26 weeks50+33%
2025-12-142026-06-07
Mix2490d
- Insider9(38%)
- Other6(25%)
- SEC Filings6(25%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- INSIDERDirector Nielsen Kirk G. was granted 8,720 shares (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERDirector Jain Mudit K. was granted 8,720 shares, increasing direct ownership by 154% to 14,370 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERDirector Slattery Joseph P was granted 8,720 shares, increasing direct ownership by 28% to 39,365 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERDirector Hill, Mitch C. was granted 8,720 shares (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERDirector Ballinger Kevin J. was granted 8,720 shares (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERDirector Shadan Martha was granted 8,720 shares (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERDirector Dale Michael D was granted 29,005 shares (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dale Michael D3 - CVRx, Inc. (0001235912) (Issuer)
- SECCVRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CVRx, Inc. (0001235912) (Filer)
- SECSEC Form SD filed by CVRx Inc.SD - CVRx, Inc. (0001235912) (Filer)
- PRCVRx to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceMINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026. The Company's presentation will begin at 8:00 a.m. (ET). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx i
- PRCVRx to Present at the William Blair 46th Annual Growth Stock ConferenceMINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx is a
- PRCVRx Announces Humana Medicare Advantage Coverage Policy for Barostim TherapyMINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. Humana, a national health insurance company with the second largest Medicare Advantage program in the U.S., provides coverage to approximately 5.2 million Medicare Advantage members across 46 states. The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled
- SECSEC Form 10-Q filed by CVRx Inc.10-Q - CVRx, Inc. (0001235912) (Filer)
- SECCVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Reports First Quarter 2026 Financial and Operating ResultsMINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarterU.S. revenue for the first quarter of 2026 was $13.7 million, an increase of 22% over the prior year quarterActive implanting centers in the U.S. grew to 257 as of March 31, 2026, as compared to 227 as of March 3
- PRCVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded PopulationMINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the landmark BENEFIT-HF trial at North Central Heart - a division of the Avera Heart Hospital, in Sioux Falls, S.D. by Dr. Orvar Jonsson. BENEFIT-HF is expected to be one of the largest therapeutic cardiac device trials ever performed in heart failure, enrolling 2,500 patients at approximately 150 centers in the United States and Germany. The prospective, randomized, controlled, multicenter trial is suppo
- PRCVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, p
- PRCVRx Announces Nomination of Michael Dale for Election to the Board of DirectorsMINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026. "Michael has achieved an outstanding record of commercial success in the medical device industry, and I'm excited for him to join our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "His extensive experience leading high growth organizations, both as an executi
- SECSEC Form DEFA14A filed by CVRx Inc.DEFA14A - CVRx, Inc. (0001235912) (Filer)
- SECSEC Form DEF 14A filed by CVRx Inc.DEF 14A - CVRx, Inc. (0001235912) (Filer)
- SECCVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - CVRx, Inc. (0001235912) (Filer)
- PRCVRx Reports Preliminary First Quarter 2026 Financial ResultsDelivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by our market access teamFirst site activated in BENEFIT-HF clinical trial MINNEAPOLIS, April 13, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited first quarter 2026 financial
- INSIDERChief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
- INSIDERCHIEF HUMAN RESOURCES OFFICER Morrison Gregory was granted 34,000 shares (SEC Form 4)4 - CVRx, Inc. (0001235912) (Issuer)
CVRX FAQ
6 questionsWhere does CVRX stock trade?
CVRx Inc. (CVRX) is listed on NASDAQ.What sector and industry is CVRX in?
CVRx Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did CVRx Inc. go public?
CVRx Inc. (CVRX) completed its IPO in 2021.What are analysts saying about CVRX?
CVRx Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight with a $700.00 price target on 2025-05-09. Recent price targets range from $700.00 to $2300.00.What companies are similar to CVRX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare CVRX side-by-side with any of them on Quantisnow.How can I track CVRX on Quantisnow?
Quantisnow aggregates CVRx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVRX to receive live email and push alerts on every new disclosure.